Breakthrough Prize Awarded to Gene Therapy Team for Restoring Lost Vision

The Breakthrough prize, often referred to as the 'Oscar of science', has been awarded to a team of scientists for their groundbreaking work in gene therapy. Jean Bennett, a molecular biologist, and Albert Maguire, an ophthalmologist, who met while dissecting a brain at Harvard Medical School, have been recognized for their 25-year-long project that led to the development of Luxturna, the first approved gene therapy for blindness.

The therapy has transformed the lives of people born with Leber congenital amaurosis (LCA), a genetic disorder that typically causes total blindness by early adulthood. The treatment, which smuggles a working version of the gene into retinal cells, has shown profound improvements in patients, with one patient describing seeing their child's face for the first time.

The $3m prize is shared with physician Katherine High, who worked with Bennett and Maguire on the project. The couple's work is a testament to their dedication and perseverance, with Bennett noting that she was 'overwhelmed' by the news and describing it as one of the most 'miraculous eureka moments' she could imagine.

Bennett also expressed concerns about the US administration's attacks on science, warning that it could 'cause damage for generations to come' and lead to a brain drain that the country would struggle to recover from.

The Breakthrough prizes, founded by Silicon Valley entrepreneurs, recognize outstanding achievements in life sciences, mathematics, and physics. Other prizes awarded included work on a gene therapy for sickle cell anaemia and beta thalassaemia, and the discovery of genetic drivers of frontotemporal dementia and ALS.